Thus, piceatannol also improves hepatic glycemic control by activating adenosine monophosphate-activated protein kinase (AMPK) through phosphorylation while ameliorating serum lipid profile in mice inhibiting the lipogenic flux mediated by ACC and fatty acid synthase (FAS) expression [42] Piceatannol-mediated AMPK phosphorylation also induces autophagy, a process reported to be dysregulated in NAFLD [43]. Here, FAS is linked to metabolic dysfunction-associated steatotic liver disease.